source
- Novo and Pfizer say MFN pricing agreements remain unchanged despite Democratic gains in CongressOn their third‑quarter earnings calls, the CEOs of Novo Nordisk and Pfizer said the Most Favored Nation drug‑pricing contracts they signed under the previous administration are still in effect and…
- FDA urges biosimilar makers to adopt alternatives to clinical efficacy trialsFDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…